FY2025 EPS Estimates for ABOS Reduced by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its earnings per share (EPS) estimate for Acumen Pharmaceuticals for FY2025, projecting a loss of ($2.29), down from a previous estimate of ($1.92), highlighting a significant reduction in expectations.
• Acumen Pharmaceuticals reported a quarterly EPS of ($0.68), which missed analysts' expectations of ($0.54) by ($0.14).
• Citigroup has initiated coverage on Acumen Pharmaceuticals with a "buy" rating and set a price target of $4.00 for the stock.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Acumen Pharmaceuticals in a note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($2.29) per share for the year, down from their previous forecast of ($1.92). The consensus estimate for Acumen Pharmaceuticals' current full-year earnings is ($1.56) per share. Cantor Fitzgerald also issued estimates for Acumen Pharmaceuticals' FY2026 earnings at ($1.45) EPS.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.14).

Separately, Citigroup assumed coverage on Acumen Pharmaceuticals in a research note on Tuesday, June 17th. They set a "buy" rating and a $4.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $6.33.

Acumen Pharmaceuticals Stock Up 2.2%

ABOS stock traded up $0.03 on Friday, hitting $1.41. 154,972 shares of the company's stock were exchanged, compared to its average volume of 329,395. Acumen Pharmaceuticals has a 12-month low of $0.8551 and a 12-month high of $3.36. The firm has a 50 day moving average price of $1.32 and a two-hundred day moving average price of $1.22. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.97 and a current ratio of 5.97. The stock has a market cap of $85.41 million, a P/E ratio of -0.62 and a beta of 0.14.

Institutional Trading of Acumen Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in shares of Acumen Pharmaceuticals by 1,387.2% in the 4th quarter. JPMorgan Chase & Co. now owns 937,908 shares of the company's stock valued at $1,613,000 after buying an additional 874,842 shares during the period. Hudson Bay Capital Management LP lifted its holdings in shares of Acumen Pharmaceuticals by 7.1% in the 2nd quarter. Hudson Bay Capital Management LP now owns 825,004 shares of the company's stock valued at $957,000 after buying an additional 55,004 shares during the period. Two Sigma Advisers LP lifted its holdings in shares of Acumen Pharmaceuticals by 6.4% in the 4th quarter. Two Sigma Advisers LP now owns 499,100 shares of the company's stock valued at $858,000 after buying an additional 30,000 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Acumen Pharmaceuticals in the 2nd quarter valued at about $291,000. Finally, Jane Street Group LLC lifted its holdings in shares of Acumen Pharmaceuticals by 1,526.0% in the 2nd quarter. Jane Street Group LLC now owns 175,670 shares of the company's stock valued at $204,000 after buying an additional 164,866 shares during the period. Hedge funds and other institutional investors own 71.01% of the company's stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.